Novavax has started human tests to evaluate a combination of the Covid vaccine and the flu vaccine. This was announced by the US company, announcing today the publication in ‘The Lancet Infectious Diseases’ of the complete phase 3 data relating to NanoFlu *, a quadrivalent influenza vaccine with adjuvant. Positive results in terms of both safety and efficacy, for which Novavax says it is “encouraged”, especially because “we have recently launched a phase 1-2 study that combines NanoFlu with our candidate Covid-19 vaccine”.
As for the NanoFlu trial, it examined the immunogenicity and safety of the product in the elderly, comparing its candidate with the leading quadrivalent influenza vaccine authorized in the US. NanoFlu “proved to be well tolerated – Novavax reports – and produced significantly better humoral and cellular immune responses than the comparator vaccine”.